リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson’s disease」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson’s disease

Sekiya, Hiroaki Tsuji, Asato Hashimoto, Yuki Takata, Mariko Koga, Shunsuke Nishida, Katsuya Futamura, Naonobu Kawamoto, Michi Kohara, Nobuo Dickson, Dennis W. Kowa, Hisatomo Toda, Tatsushi 神戸大学

2022.09.06

概要

The pathological hallmarks of Parkinson’s disease (PD) are α-synuclein (αSYN)-positive inclusions referred to as Lewy bodies and Lewy neurites, collectively referred to as Lewy-related pathology (LRP). LRP is thought to propagate in an ascending manner throughout the brain as the disease progresses. LRP is visible with histologic methods and is thought to represent a later stage of the disease process, while αSYN oligomers, which are not visible with routine histologic methods, are considered earlier. There is increasing evidence to suggest that αSYN oligomers may be more toxic than visible LRP. Detecting αSYN oligomers requires special techniques, and their distribution and association with clinical features are important research objectives. In this report, we describe the distribution of αSYN oligomers in multiple cortical and subcortical regions of PD using a proximity ligation assay (PLA). We observe widespread distribution of αSYN oligomers with PLA and more restricted distribution of LRP with αSYN immunohistochemistry. The distribution of αSYN oligomers differed from LRP in that αSYN oligomer burden was significantly greater in the neocortex, while LRP was greater in vulnerable subcortical regions, including the brainstem. We also found that cognitive impairment was associated with αSYN oligomers in the hippocampus. These results suggest that αSYN oligomers may be widely distributed in PD early in the disease process and that they may contribute to cognitive impairment in PD.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Alam P, Bousset L, Melki R, Otzen DE (2019) α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem 150:522–534. https://doi.org/10.1111/jnc.14808

2. Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M et al (1998) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 96:439–444. https:// doi.org/10.1007/s004010050917

3. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM et al (1998) Aggrega- tion of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884

4. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J et al (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634. https://doi.org/10.1007/ s00401-009-0538-8

5. Behere A, Thörnqvist PO, Winberg S, Ingelsson M, Bergström J, Ekmark- Lewén S (2021) Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model. J Neurosci Res 99:2525–2539. https://doi.org/ 10.1002/jnr.24927

6. Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284– 2303. https://doi.org/10.1016/s0140-6736(21)00218-x

7. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. https://doi.org/10.1007/bf003 08809

8. Braak H, Del Tredici K (2008) Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–1925. https://doi.org/10. 1212/01.wnl.0000312279.49272.9f

9. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neuro- biol Aging 24:197–211. https://doi.org/10.1016/s0197-4580(02)00065-9

10. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J et al (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507–511. https://doi.org/10.1038/41650 7a

11. Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A et al (2012) Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149:1048–1059. https://doi.org/10.1016/j.cell.2012.03. 037

12. Dickson DW (2018) Neuropathology of Parkinson disease. Parkinsonism Relat Disord 46(Suppl 1):S30–S33. https://doi.org/10.1016/j.parkreldis. 2017.07.033

13. Dickson DW (2012) Parkinson’s disease and parkinsonism: neuropathol- ogy. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshpe rspect.a009258

14. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157. https://doi.org/10.1016/ s1474-4422(09)70238-8

15. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707. https://doi.org/10.1002/mds.21507 (quiz 1837)

16. Espay AJ (2022) Movement disorders research in 2021: cracking the para- digm. Lancet Neurol 21:10–11. https://doi.org/10.1016/s1474-4422(21) 00413-0

17. Gallea C, Ewenczyk C, Degos B, Welter ML, Grabli D, Leu-Semenescu S et al (2017) Pedunculopontine network dysfunction in Parkinson’s disease with postural control and sleep disorders. Mov Disord 32:693–704. https://doi.org/10.1002/mds.26923

18. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of Lewy pathology. Nat Rev Neurol 9:13–24. https://doi.org/10.1038/nrneurol. 2012.242

19. Halliday GM, Holton JL, Revesz T, Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122:187–204. https://doi.org/10.1007/s00401-011-0852-9

20. Hatton C, Reeve A, Lax NZ, Blain A, Ng YS, El-Agnaf O et al (2020) Complex I reductions in the nucleus basalis of Meynert in Lewy body dementia: the role of Lewy bodies. Acta Neuropathol Commun 8:103. https://doi. org/10.1186/s40478-020-00985-8

21. Hustad E, Aasly JO (2020) Clinical and imaging markers of prodromal Parkinson’s disease. Front Neurol 11:395. https://doi.org/10.3389/fneur. 2020.00395

22. Ingelsson M (2016) Alpha-synuclein oligomers-neurotoxic molecules in Parkinson’s disease and other Lewy body disorders. Front Neurosci 10:408. https://doi.org/10.3389/fnins.2016.00408

23. Jellinger KA (2008) A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 116:1–16. https://doi.org/ 10.1007/s00401-008-0406-y

24. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 34:284–295. https://doi.org/10.1111/j.1365-2990.2007.00923.x

25. Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW (2021) Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener 16:83. https://doi.org/10.1186/s13024-021-00501-z

26. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkin- son’s disease. Nat Med 14:504–506. https://doi.org/10.1038/nm1747

27. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503. https://doi.org/ 10.1038/nm1746

28. Mazzetti S, Basellini MJ, Ferri V, Cassani E, Cereda E, Paolini M et al (2020) α-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson’s disease. Brain 143:920–931. https://doi.org/10. 1093/brain/awaa008

29. Mendez I, Viñuela A, Astradsson A, Mukhida K, Hallett P, Robertson H et al (2008) Dopamine neurons implanted into people with Parkinson’s disease survive without pathology for 14 years. Nat Med 14:507–509. https://doi.org/10.1038/nm1752

30. Miki Y, Tanji K, Shinnai K, Tanaka MT, Altay F, Foti SC et al (2022) Pathologi- cal substrate of memory impairment in multiple system atrophy. Neuro- pathol Appl Neurobiol. https://doi.org/10.1111/nan.12844

31. Murakami A, Koga S, Sekiya H, Oskarsson B, Boylan K, Petrucelli L et al (2022) Old age amyotrophic lateral sclerosis and limbic TDP-43 pathol- ogy. Brain Pathol. https://doi.org/10.1111/bpa.13100

32. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142:1503–1527. https://doi.org/ 10.1093/brain/awz099

33. Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D et al (2019) Dementia with Lewy bodies: an update and outlook. Mol Neuro- degener 14:5. https://doi.org/10.1186/s13024-019-0306-8

34. Parkkinen L, Pirttilä T, Alafuzoff I (2008) Applicability of current stag- ing/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 115:399–407. https://doi.org/10.1007/ s00401-008-0346-6

35. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424

36. Roberts RF, Wade-Martins R, Alegre-Abarrategui J (2015) Direct visualiza- tion of alpha-synuclein oligomers reveals previously undetected pathol- ogy in Parkinson’s disease brain. Brain 138:1642–1657. https://doi.org/10. 1093/brain/awv040

37. Sekiya H, Koga S, Otsuka Y, Chihara N, Ueda T, Sekiguchi K et al (2022) Clinical and pathological characteristics of later onset multiple system atrophy. J Neurol 269:4310–4321. https://doi.org/10.1007/ s00415-022-11067-1

38. Sekiya H, Kowa H, Koga H, Takata M, Satake W, Futamura N et al (2019) Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation. Acta Neuropathol 137:455–466. https://doi.org/10.1007/s00401-019-01961-w

39. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkin- son’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469–6473. https://doi.org/10.1073/pnas.95.11.6469

40. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. https://doi. org/10.1038/42166

41. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791–1800. https://doi.org/10.1212/wnl.58.12.1791

42. Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A et al (2015) Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun 3:35. https://doi.org/10.1186/ s40478-015-0215-1

43. Uemura MT, Robinson JL, Cousins KAQ, Tropea TF, Kargilis DC, McBride JD et al (2022) Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol 143:15–31. https://doi.org/10.1007/s00401-021-02383-3

44. Wakabayashi K, Matsumoto K, Takayama K, Yoshimoto M, Takahashi H (1997) NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson’s disease. Neurosci Lett 239:45–48. https://doi.org/10.1016/ s0304-3940(97)00891-4

45. Weihofen A, Liu Y, Arndt JW, Huy C, Quan C, Smith BA et al (2019) Devel- opment of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis 124:276–288. https://doi.org/10.1016/j.nbd.2018. 10.016

46. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194–4199. https://doi.org/10.1073/pnas.1100976108

47. Wong YC, Krainc D (2017) α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med 23:1–13. https://doi.org/ 10.1038/nm.4269

48. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG (2008) Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 70:1042–1048. https://doi.org/10.1212/01.wnl.0000306697. 48738.b6

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る